5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterizing the immune phenotype of FGFR3 mutated upper tract urothelial carcinoma (UTUC) using single-cell (sc)RNA-sequencing (seq)
    Meeting Abstract

    Katims, A. B.; Kuo, F.; Reisz, P.; Tracey, A.; Thomas, J.; Yip, W.; Merghoub, T.; Bochner, B. H.; Pietzak, E. J.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC)
    Meeting Abstract

    Katims, A. B.; Lenis, A. T.; Shah, R. H.; Chu, C. E.; Ratna, N.; Regazzi, A. M.; Pietzak, E. J.; Aggen, D. H.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K
    Meeting Abstract

    O'Donnell, P. H.; Rosenberg, J. E.; Hoimes, C. J.; Petrylak, D. P.; Milowsky, M. I.; McKay, R. R.; Srinivas, S.; Friedlander, T. W.; Ramamurthy, C.; Bilen, M. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study
    Meeting Abstract

    Milowsky, M. I.; O'Donnell, P. H.; Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Moon, H. H.; Friedlander, T. W.; Mar, N.; McKay, R. R.; Srinivas, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer
    Meeting Abstract

    Aggen, D. H.; Hong, D. S.; Clarke, J. M.; Asch, A. S.; Calvo, E.; Zugazagoitia, J.; Butler, M. O.; Moreno, V.; Cervantes, A.; Van Tine, B. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC)
    Meeting Abstract

    Teo, M. Y.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Donahue, T. F.; Goh, A. C.; Cha, E. K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Automated analysis of FDG-PET/CT imaging to monitor heterogeneous disease response in metastatic castration-resistant prostate cancer
    Meeting Abstract

    Barnett, E.; Woo, S.; Perk, T. G.; Munian-Govindan, R.; Lokre, O.; Gajar, R. N.; Erazo, T.; Carbone, E.; Morris, M. J.; Vargas, H. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)
    Meeting Abstract

    Nguyen, P. L.; Kollmeier, M.; Rathkopf, D. E.; Hoffman, K. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)
    Meeting Abstract

    Aggarwal, R. R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Laccetti, A. L.; Chatta, G. S.; Iannotti, N.; Kyriakopoulos, C.; Villaluna, K.; Le Moigne, R.; Cesano, A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save